Glass Lewis Proxy Paper Report Recommends “FOR” AIkido Pharma Inc. Share Split Proposal

Analyst Firm Agrees Reverse Split Is In Company’s Best Interest

NEW YORK, April 22, 2022 /PRNewswire/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) announced today that, the April 20, 2022independent analyst firm Proxy Paper Glass Lewis has published a report (“GL Report”) providing an analysis of the proposals contained in the Company’s “Proxy Statement for 2022 Annual Meeting of Stockholders” May 20, 2022“, which was filed with the Securities and Exchange Commission on April 122022. With respect to proposal (4) in the Proxy Circular to effect a consolidation of the Company’s common stock, the GL Report recommends “FOR” the proposal.

Anthony HayesCEO of AIkido, said, “The company’s board of directors is confident that the proposed combination is in the best interest of the company and the shareholders. It is important to note that the reverse business combination would have no dilutive effect on our shareholders. objective in proposing a potential consolidation is to increase the trading price per share of our common stock to enable the company to regain compliance with the Nasdaq minimum bid requirement. The board also believes that the proposed consolidation will improve the acceptability and marketability of our common stock to the financial community and the investing public. In his independent report, Glass Lewis recommends “FOR” the proposal and agrees with the Board that it is in the best interests of the Company. We encourage all shareholders to read the proxy information fully and carefully and then vote your shares. »

For more information on Glass Lewis, see

About AIkido Pharma Inc.

AIkido Pharma Inc. was originally established in 1967 and is a biotechnology company with a diverse portfolio of small molecule anticancer and antiviral therapeutics. The Company’s platform consists of patented technology sourced from leading universities and researchers, and we are currently developing an innovative therapeutic drug platform through strong partnerships with educational institutions. world-renowned, including the University of Texas in Austin and the University of Maryland to Baltimore. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer and prostate cancer. We are constantly looking to expand our pipeline to address unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that could potentially inhibit the replication of several viruses, including influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebola virus and Marburg virus.

Forward-looking statements

Certain statements contained in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may”, “could”, “will”, “should”, “believe”, “expect”, “anticipate”, “estimate”, “continue”, “predict”, “plan” , “project”, “” Although the Company believes that these forward-looking statements are reasonable, undue reliance should not be placed on these forward-looking statements, which are based on information available to us as of the date of this release. These forward-looking statements are based on current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company’s filings with the SEC, without limitation to risk associated with its activities contained therein. Therefore, actual results could differ materially. The Company expressly disclaims any obligation to update or change any statements, whether as a result of new information, future events or otherwise, except as required by law.


Investor Relations:

R.I. Hayden
Brett MaasManaging Partner
Telephone: (646) 536-7331
E-mail: [email protected]

AIkido Pharma Inc.
Phone: 212-745-1373
E-mail: [email protected]

SOURCEAIkido Pharma Inc.

About Jason Norton

Check Also

Low stock price triggers Nasdaq delisting warning for AlerisLife

AlerisLife (Nasdaq: ALR) needs to raise its stock price or face possible delisting from the …